BIO ESSENCE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.26 USD | -49.02% |
|
-.--% | -49.02% |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 18.15 | 19.38 |
| Enterprise Value (EV) 1 | 22.77 | 22.86 |
| P/E ratio | -22.4 x | -18.9 x |
| Yield | - | - |
| Capitalization / Revenue | 18.4 x | 35.1 x |
| EV / Revenue | 23.1 x | 41.5 x |
| EV / EBITDA | -31.2 x | -29.6 x |
| EV / FCF | -51.4 x | -31.8 x |
| FCF Yield | -1.95% | -3.15% |
| Price to Book | -5.61 x | -11.7 x |
| Nbr of stocks (in thousands) | 33,009 | 38,009 |
| Reference price 2 | 0.5500 | 0.5100 |
| Announcement Date | 3/30/23 | 4/15/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.9846 | 0.8263 | 0.9587 | 0.888 | 0.9858 | 0.5515 |
| EBITDA 1 | -1.461 | -1.686 | -0.7993 | -0.8217 | -0.7288 | -0.7716 |
| EBIT 1 | -1.5 | -1.718 | -0.8326 | -0.8575 | -0.7828 | -0.789 |
| Operating Margin | -152.38% | -207.9% | -86.84% | -96.57% | -79.41% | -143.07% |
| Earnings before Tax (EBT) 1 | -1.455 | -1.7 | -0.5925 | -0.6443 | -0.8064 | -0.8001 |
| Net income 1 | -1.459 | -1.703 | -0.5958 | -0.6476 | -0.8097 | -0.9719 |
| Net margin | -148.15% | -206.15% | -62.15% | -72.93% | -82.14% | -176.22% |
| EPS 2 | -0.0454 | -0.0519 | -0.0180 | -0.0196 | -0.0245 | -0.0270 |
| Free Cash Flow 1 | -0.4367 | -1.005 | -0.3204 | -0.8512 | -0.4432 | -0.7201 |
| FCF margin | -44.35% | -121.57% | -33.42% | -95.85% | -44.96% | -130.57% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 7/26/19 | 11/25/20 | 4/14/21 | 3/31/22 | 3/30/23 | 4/15/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.11 | 2.26 | 2.95 | 3.96 | 4.61 | 3.48 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.0728 x | -1.337 x | -3.693 x | -4.822 x | -6.33 x | -4.509 x |
| Free Cash Flow 1 | -0.44 | -1 | -0.32 | -0.85 | -0.44 | -0.72 |
| ROE (net income / shareholders' equity) | -172% | 372% | 41.6% | 30.8% | 28.6% | 32.8% |
| ROA (Net income/ Total Assets) | -64.5% | -65.1% | -25.1% | -30.2% | -30.1% | -23.4% |
| Assets 1 | 2.262 | 2.618 | 2.37 | 2.141 | 2.687 | 4.148 |
| Book Value Per Share 2 | 0.0100 | -0.0300 | -0.0500 | -0.0700 | -0.1000 | -0.0400 |
| Cash Flow per Share | - | - | 0 | 0 | 0 | 0 |
| Capex 1 | 0.1 | 0.03 | 0.01 | 0.12 | 0.06 | 0 |
| Capex / Sales | 9.82% | 3.35% | 0.77% | 13.46% | 6% | 0.66% |
| Announcement Date | 7/26/19 | 11/25/20 | 4/14/21 | 3/31/22 | 3/30/23 | 4/15/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -49.02% | 9.88M | |
| +26.08% | 662B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 289B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B |
- Stock Market
- Equities
- BIOE Stock
- Financials Bio Essence Corporation